DLA Piper advised Iovance, and Latham & Watkins advised the underwriters. Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) announced the pricing of an underwritten public offering of 20,000,000 shares...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises eFFECTOR Therapeutics in US$7.5 million registered direct offering. eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs)...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises Phathom Pharmaceuticals in pricing of US$130 million public offering of common stock. Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Icosavax on the offering. Icosavax, Inc. (Nasdaq: ICVX) has announced that it has entered into a securities purchase agreement with investors in a...
You must be a Standard 1 Year member to access this content.
Cooley advised Reneo, and Latham & Watkins advised the underwriters and placement agents. Reneo Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of...
You must be a Standard 1 Year member to access this content.
Paul, Weiss, Rifkind, Wharton & Garrison represented Merck, Latham & Watkins represented Prometheus, Skadden represented the financial advisors on the deal. Prometheus Biosciences, Inc. have entered...
You must be a Standard 1 Year member to access this content.
Cooley advises Travere Therapeutics, and Latham & Watkins advises the underwriters. Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced the pricing of an underwritten public offering of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
You must be a Standard 1 Year member to access this content.
Cooley advised Longboard Pharmaceuticals on the offering, and Latham & Watkins advised the underwriters involved. Longboard Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public...
You must be a Standard 1 Year member to access this content.
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Alphatec in the transactions. Alphatec Holdings, Inc. (Nasdaq: ATEC), a medical technology company focusing on surgical treatment for spinal disorders has...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP advised Erasca on the offering. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
You must be a Standard 1 Year member to access this content.
